TY  - JOUR
T1  - Monkeypox Resurgence: Transmission, Clinical Features, and Advances in Countermeasures and Treatment
A1  - Fathimath Ina Shareef
A1  - Mariyam Luba Abdulla
A1  - Aminath Efa Ibrahim
A1  - Kannan Subbaram
JF  - Journal of Medical Sciences and Interdisciplinary Research
JO  - J Med Sci Interdiscip Res
SN  - 3108-4826
Y1  - 2022
VL  - 2
IS  - 2
DO  - 10.51847/3C4K4xyQjt
SP  - 40
EP  - 48
N2  - The present study aimed to investigate the transmission, clinical features, and advances in countermeasures and treatment of monkeypox. Monkeypox is a DNA virus in the Poxviridae family, specifically classified under the Orthopoxvirus genus. Historically confined to central and western Africa, monkeypox made global headlines in 2022 due to widespread outbreaks in regions where it was previously rare, including North America, Europe, Asia, and Australasia. On 23 July 2022, the World Health Organization (WHO) declared the outbreak a public health emergency of international concern (PHEIC), prompting global efforts to curb its spread. Though monkeypox is primarily a zoonotic disease, human-to-human transmission occurs through direct or indirect contact with infected bodily fluids, skin lesions, or respiratory droplets. The 2022 outbreak saw a higher incidence among homosexual men, and in pregnant women, the virus was linked to congenital infection and miscarriage. Clinically, monkeypox progresses through four stages of lesions: macules, papules, vesicles, pustules, and scabs. Complications such as septicemia, pneumonia, eye infections, and neurological problems have also been reported. Available antiviral treatments include tecovirimat (TPOXX), cidofovir, and brincidofovir, while vaccines such as LC16, MVA-BN (JYNNEOS in the U.S.), and ACAM2000 offer preventive measures.
UR  - https://smerpub.com/article/monkeypox-resurgence-transmission-clinical-features-and-advances-in-countermeasures-and-treatment-pcutuflku00fhzl
ER  -